Dare Bioscience (DARE) Gains from Investment Securities (2013 - 2014)
Dare Bioscience's (DARE) quarterly Gains from Investment Securities came in at -$504000.0 in Q1 2014, down 118.18% YoY from $2.8 million in Q1 2013, and down 1300.0% on a QoQ basis from $42000.0 in Q4 2013.
Dare Bioscience (DARE) Gains from Investment Securities (2013 - 2014) Analysis & Trends
Dare Bioscience (DARE) has 2 years of Gains from Investment Securities data on file, last reported at -$504000.0 in Q1 2014.
- Quarterly Gains from Investment Securities fell 118.18% year-over-year to -$504000.0 in Q1 2014, while the trailing twelve-month figure through Dec 2014 was -$504000.0 (down 149.5% YoY) and the FY2021 annual result came in at $44286.0, changed N/A from the prior year.
- Gains from Investment Securities retreated to -$504000.0 in Q1 2014, from $42000.0 in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $42000.0 in Q4 2013 to a low of -$504000.0 in Q1 2014.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Dare Bioscience | 12.36 Mn | -256,055.23 | -132,343.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2014 | -504,000.00 |
| Mar 31, 2014 | -504,000.00 |
| Dec 31, 2013 | 42,000.00 |
| Dec 31, 2013 | 42,000.00 |
| Sep 30, 2013 | 7,000.00 |
| Sep 30, 2013 | 7,000.00 |
| Jun 30, 2013 | -20,000.00 |
| Jun 30, 2013 | -20,000.00 |
| Mar 31, 2013 | -231,000.00 |
| Mar 31, 2013 | -231,000.00 |